Background: More data are needed to define factors that predict long-term success after
Introduction
Lentigo maligna (LM), a melanoma in situ on chronically sun-damaged skin, mainly affects elderly patients and has a strong predilection for the head and neck region (1, 2) . Several therapeutic modalities, such as surgery, cryotherapy (3, 4) and radiotherapy (5) (6) (7) , are used.
Surgical excision with safety margins (usually 5 millimeters) is the treatment of choice.
Imiquimod is a topical immune response modifier that has been recently suggested to be a valuable alternative treatment to surgery in LM, especially in cases with larger lesions located on the face in elderly and comorbid patients (1, (8) (9) (10) (11) (12) (13) (14) (15) (16) , when surgery is not indicated or cannot be performed. It has also been proposed as a neo-or post-adjuvant treatment option to operative procedures (9, (12) (13) (14) . Recurrence of LM or LMM after treatment with imiquimod has also been observed in some patients (17) .
The aim of our study was to evaluate the response of LM to nonsurgical treatment with 5% imiquimod cream in a cohort of patients with long-term follow-up. Furthermore, the role of demographic, clinical and histological features for the long-term efficacy of imiquimod treatment in LM patients was assessed. The following patient data were analyzed: age at the beginning of the therapy, sex and Fitzpatrick skin phototype, side effects and clinical response during therapy, size and location of the lesion, occurrence of relapse, time from the beginning of the therapy to relapse, date of the last clinical follow-up, death and other skin malignancies.
Histological evaluation: Punch biopsies and excisional biopsies were fixed in formalin and embedded in paraffin using routine techniques. The diagnoses of LM was made by at least two board certified dermatopathologists by analyzing hematoxylin-eosin stained slides, as well as immunohistochemical stainings for melan-A antigen. The total number of melanocytes, the number of basal and suprabasal melanocytes, and the number of pagetoid spreading melanocytes (i.e., melanocytes above the basal and suprabasal layers of the epidermis) were assessed on melan-A stained tissue sections using a conventional light microscopy with an integrated millimetric scale. All of the parameters are indicated as cells/positive events per mm epidermis. As the epidermis in these mainly elderly individuals with sun damaged skin was always very thin, counting cells linearly along the length of the epidermis and indicating cells/events per mm epidermis was more reliable than counting cells/events per square mm. Furthermore, the maximal epidermal depth of the melanocytes, i.e., usually the maximal depth of the melanocytes along the hair follicle, was estimated.
Similar to tumor thickness (according to Breslow), the distance between the stratum granulosum and the deepest melanocyte was measured. The maximal extent of non-invasive melanocytes was called epidermal tumor thickness. were calculated based on the cumulative hazard and point wise log (survival). Otherwise, the methods used to conduct tests (p-values) and CIs are specified separately. The two-sided exact Wilcoxon signed rank test was also used, whereas patients who were censored (lost to follow-up or death) were not included in this analysis.
Results:
Patient and tumor characteristics are shown in Table 1 . Eighty-nine patients (55 females and 34 males) with a median age of 72.5 y (range 38.6-93.8 y) were included in the study. Only 5 of 89 LM were located outside the face (either on the arm, neck or on the shoulders). No LM was found on the trunk or lower extremities. The treatment-induced local inflammatory reaction was generally well tolerated, but one patient had to discontinue treatment after 63 days due to a generalized pruritic macular papular rash. Other side effects, including hypopigmentation, persistent erythema and telangiectasia at the treatment site, as well as malaise, hair-loss, sleeping problems, herpes labialis and swollen eyes in the morning, were observed in 16 patients (18%). Moreover, one patient developed persistent vitiligo-like white patches outside the treated area (on the dorsal surfaces of his hands). To determine the accuracy of the bioptical assessment of LM lesions, a preliminary study was performed in ten consecutive cases. All four parameters (the number of total melanocytes, number of basal and suprabasal melanocytes, number of pagetoid spreading melanocytes per mm epidermis and tumor thickness) were simultaneously evaluated with a punch biopsy and in completely excised LM lesions. All four parameters were higher or equal in the punch biopsies compared to the excisional specimens, indicating that the biopsies were representative and that no underestimation of the extent of the disease was made (supplementary Figure) .
The total number of melanocytes, basal and suprabasal melanocytes, number of pagetoid spreading melanocytes per mm of epidermis and tumor thickness obtained from baseline biopsies were further compared between relapsed and non-relapsed patients (Figure 3) .
Interestingly, all four parameters were increased in the baseline biopsies of the relapsed patients, indicating an increased risk of recurrence. Statistical significance was observed only for the total melanocytes.
Discussion.
Lentigo maligna is the most common melanoma of the sun-damaged skin of the elderly (in our study, the median age was 72.5 y). As also confirmed by our results, it has a certain predilection for the facial region (in our study population, 84 out of 89 LM, that is 94.4%) (1, 18) . The rate of progression of LM to invasive melanoma is low (<5% overall), but the exact conditions necessary for these transformations have yet to be elucidated (19, 20) . Jeffrey et al. postulate that the recurrence rate following nonsurgical therapies ranges between 20% and 100%. The recurrence rate after radiotherapy ranges from 1% to 19% and is often followed by radiodermatitis, tissue destruction, and scarring and may promote the development of squamous-cell carcinomas; therefore, it is not the therapy of choice.
Similarly, cryotherapy with a recurrence rate between 0 and 40% (21) is not the best therapeutic option. Surgical excision remains the treatment of choice for LM, with a recurrence rate of 3% after Mohs surgery. Nevertheless, complete surgical treatment is sometimes difficult to perform, either because of patients' comorbidities or due to the risk of cosmetic disfigurement. Its limits comprise the location and size of the lesion (9, (22) (23) . A good therapeutic alternative in these cases is topical imiquimod, especially when aesthetic issues are involved (9) . It has been demonstrated to be a very efficient therapy with a relatively low recurrence rate (3, 15, 24, 25) . According to Naylor et al, imiquimod shows no relapse in over 80% of cases (26) . Imiquimod is a topical immune response modifier that acts through binding toll-like receptors 7 and 8 on dendritic cells, macrophages and neutrophils (27) . In LM, imiquimod recruits CD68+ macrophages and cells involved in cytotoxic T-cell responses, including CD 8+ T cells (28) . It regulates genes involved in different aspects of the immune response, apoptosis and oncogenesis (29) .
The principle aim of our study was to assess the risk factors of LM relapse after treatment with imiquimod based on an evaluation of the demographic, clinical and histological features of patients and LM lesions. As demonstrated, in relapsed patients (18% of the study population) the baseline number of the total melanocytes, as well as the basal and suprabasal, and pagetoid spreading melanocytes, per mm epidermis compared to those of non-relapsed patients, appeared to be significantly increased and might be an indicator of the risk of recurrence. To our knowledge, this is the first time that the previously mentioned typing and assessment of melanocytes in LM biopsies has been used. This easy-to-perform, inexpensive and statistically relevant method has only been validated for LM patients treated with imiquimod.
To date, visible signs of inflammation at the site of treatment and apparent lesion clearance have been considered to be predictors of a good response to/efficacy of the imiquimod treatment (12, 13). Our results confirm that the visible signs of inflammation are often correlated with successful outcomes; however, this relation was not statistically significant (95% CI, 0.18-2.37, p-value: 0.521). Also, other well established diagnostic modalities, including dermoscopy (30) and in vivo reflectance confocal microscopy (31), have appeared to be helpful in relapse estimation, but they appear not to be statistically significant. The (10, 33) . The outcomes from studies where imiquimod was used in addition to surgical treatment (9, 12, 13) , ablative laser (14) or other topical treatments (e.g., tazarotene 0.1%) (15) demonstrated variable effects. To date, complete surgery remains the best therapeutic option for LM patients (34) (35) (36) .
In conclusion, in cases where surgery is not an option (due to an esthetically challenging localization or the patient's comorbidities), imiquimod provides favorable outcomes with a low risk of relapse, is less painful and has a lower mortality rate due to the treatment. Typing and the assessment of melanocytes in a skin biopsy is a cheap and simple method that can help predict the risk of relapse already before treatment and further contribute to the best therapeutic decision individually adjusted to each patient. 
